HAIM International

HaimBio is a South Korean biotechnology company specializing in the development of metabolic anticancer drugs that target the unique energy production pathways of malignant cells. The company's core research focuses on the Warburg Effect, aiming to selectively disrupt cancer cell metabolism without harming healthy tissue. Their lead drug candidate, NYH817100 (also known as Star-V), is a combination small molecule therapy designed to simultaneously inhibit glycolysis and oxidative phosphorylation. By starving cancer cells of their energy supply, HaimBio seeks to provide effective treatments for refractory conditions such as glioblastoma and various solid tumors. The company's approach represents a shift toward low-toxicity, metabolism-centered oncology interventions.